0001415889-23-013339.txt : 20230918 0001415889-23-013339.hdr.sgml : 20230918 20230918172623 ACCESSION NUMBER: 0001415889-23-013339 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230915 FILED AS OF DATE: 20230918 DATE AS OF CHANGE: 20230918 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Velleca Mark A. CENTRAL INDEX KEY: 0001706847 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 231261934 MAIL ADDRESS: STREET 1: 79 TW ALEXANDER DRIVE STREET 2: 4501 RESEARCH COMMONS, SUITE 100 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 4 1 form4-09182023_090915.xml X0508 4 2023-09-15 0001701541 Black Diamond Therapeutics, Inc. BDTX 0001706847 Velleca Mark A. C/O BLACK DIAMOND THERAPEUTICS, INC. ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 true true false false PRESIDENT & CEO 0 Common Stock 2023-09-15 4 A 0 5208 3.60 A 46522 D Stock Option (Right to Buy) 3.55 2023-09-17 4 A 0 1000000 0 A 2033-09-16 Common Stock 1000000 1000000 D These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 14, 2023. 25% of the shares subject to this option shall vest and become exercisable on September 17, 2024, with the remainder vesting in 36 equal monthly installments thereafter. /s/ Brent Hatzis-Schoch, Attorney-in-Fact 2023-09-18